References
- Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214–32
- Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005; 93: 884–9
- Kodaira T, Fuwa N, Tachibana H, Hidano S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 2006; 26(3B)2265–8
- Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993; 85: 95–111
- Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994; 29: 519–23
- Lawrence TS, Davis MA, Loney TL. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 1996; 56: 3203–6
- Tanaka H, Shirakawa T, Zhang Z, Hamada K, Gotoh A, Nibu K. A replication-selective adenoviral vector for head and neck cancers. Arch Otolaryngol Head Neck Surg 2005; 131: 630–4
- Mecham BH, Klus GT, Strovel J, Augustus M, Byrne D, Bozso P, et al. Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nucleic Acids Res 2004; 32: e74
- Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, Petschke B, et al. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 2006; 8: 38–45
- Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004; 64: 4294–301
- Ijuin T, Nibu K, Doi K, Inoue H, Saitoh M, Ohtsuki N, et al. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer. Acta Otolaryngol (Stockh) 2007; 127: 305–11
- Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res 2005; 11: 7683–91
- Takahashi Y, Moriwaki S, Sugiyama Y, Endo Y, Yamazaki K, Mori T, et al. Decreased gene expression responsible for post-ultraviolet DNA repair synthesis in aging: a possible mechanism of age-related reduction in DNA repair capacity. J Invest Dermatol 2005; 124: 435–42